Fudan-Zhangjiang’s JAK1 Inhibitor FZJ-003 Gel Enters Phase I Trial for Atopic Dermatitis
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349, SHA: 688505) announced that a Phase I...
HutchMed’s Elunate Shows Survival Benefit in Global CRC Study at ESMO
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced the results of the pivotal...
Jacobio’s KRAS G12C Inhibitor JAB-21822 Advances to Pivotal Phase II in NSCLC
China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has received approval from the National Medical...
Lianren Digital Health Partners with Ningbo Government on Health Data Ecosystem
Shanghai-based Lianren Digital Health has forged a strategic partnership with the People’s Government of Ningbo...
Bio-Heart Invests RMB 50M in Cardiotek to Advance Balloon-Expandable TAVR Device
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese interventional cardiovascular device maker,...
HitGen’s Vernalis Subsidiary Collaborates with Unison Medicines on Undruggable Bacterial Target
China’s HitGen Inc. (SHA: 688222) announced a strategic research collaboration between its wholly owned subsidiary,...
Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Shows Superior Booster Efficacy in Phase III Trial
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) reported positive Phase III trial results for its COVID-19...
Astellas’ Fezolinetant Hits Menopause Trial Goals in China, Eyes Global Launch
Japan’s Astellas Pharma Inc. (TYO: 4503) announced positive results from a Phase III trial of...
CellOrigin and Qilu Partner on Global CAR-iMAC Cancer Therapy Development
CellOrigin Biotech (Hangzhou) Co., Ltd, a China-based biotech firm specializing in allogeneic cell therapies, has...
Bio-Heart Plans STAR Board IPO After Hong Kong Debut to Advance Cardiovascular Therapies
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese innovator in interventional cardiovascular...
Fosun Pharma’s Controlling Shareholder to Sell 3% Stake for USD 461 Million
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its controlling shareholder, Shanghai Fosun...
SciClone Pharmaceuticals Doses First Patient in RRx-001 Phase III Study for SCLC
China-based SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) announced that the first patient has been dosed in...
Hotgen Biotech Receives UK Approvals for Monkeypox and COVID-19 Antigen Detection Kits
Shanghai-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced significant regulatory milestones in the United...
Zelgen Biopharm’s Donafenib Shows Promise in Phase III Study for RAIR-DTC
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced positive results from the Phase III...
BGI’s Stereo-seq Tech Maps Axolotl Brain Regeneration in World-First Study
China’s genomics giant BGI has revealed a landmark study using its proprietary Stereo-seq sequencing technology...
Junshi Biosciences Plans USD 572M Private Placement to Fund Drug R&D and Expansion
China’s Shanghai Junshi Biosciences Co., Ltd (SHA: 688180, HKG: 1877) announced plans to raise up...
CanSino, Livzon Win China EUAs for COVID-19 Booster Vaccines
China-based vaccine makers CanSino Biologics (HKG: 6185) and Livzon Pharmaceutical Group Inc. (HKG: 1513) have...
AWS Partners with Zhongshan to Launch Smart Manufacturing and Biomedical Digital Center
Amazon Web Services (AWS) and Zhongshan’s Bureau of Commerce announced a partnership at the China...
BoomRay Pharmaceuticals Raises USD 43M in Series A for RDC Pipeline Expansion
China’s BoomRay Pharmaceuticals, a specialist in radionuclide drug conjugates (RDCs), reportedly raised nearly RMB 300...